Breast cancer remains a significant challenge, particularly in aggressive forms like triple-negative breast cancer (TNBC). This is a type of breast cancer where the tumour cells lack hormonal receptors, like estrogen receptors. This means that common breast cancer treatments targeting these receptors are not effective against TNBC, making it more challenging to treat and prone to spreading. Scientists are constantly searching for new ways to target the underlying mechanisms that allow these cancer cells to grow and spread unchecked. 

Researchers have shown how subtle nanoscale changes to the spacing between cancer cells can enhance ultrasound treatments' effectiveness in killing those cells.

A new study analyses some of the most widely used databases and applications or algorithms available for protein mutations and predicting disease-causing mutations among them.

Indian Institute of Science (IISc) announced the establishment of the Param Hansa Centre for Computational Oncology (PHCCO) on 3rd November 2023. Funded by Param Hansa Philanthropies (PHP), a charitable organization with a commitment to scientific research, the Centre was officially inaugurated on 2nd November 2023, marking a significant step towards the integration of cutting-edge computational methodologies with groundbreaking cancer research in India.

Scientists say you can now use Osimertinib -a cancer drug- just once a week instead of daily and still be safe from tumour regrowths.

Study identifies the role of DLX1 gene in prostate cancer demonstrating how its elimination leads to reduced carcinogenesis in mice models

Research finds that cancer cells of different sizes and stiffness are more invasive than a group of uniform cells.

Researchers have found how cancer cells hoodwink the biological clock controls and use them to promote tumour growth.

Researchers have identified two groups of genes that switch activity and help cancer cells evade therapy and spread aggressively.

Researchers have identified a set of proteins that can distinguish between ovarian cancer and benign tumors.